Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 14, 2026; 32(46): 121840
Published online Dec 14, 2026. doi: 10.3748/wjg.121840
Published online Dec 14, 2026. doi: 10.3748/wjg.121840
Table 1 Parameters for the stepwise enrichment approach of age-male-albumin-bilirubin-platelets scores used in the model[16]
| Parameter | Base-case value | Uncertainty interval | Distribution |
| Proportion of individuals entering each stratification step | |||
| First: AMAP assessment | 1 | ||
| Second: AMAP-2 assessment | 0.8953 | 0.7162-1 | Triangular (0.7162, 0.8953, 1) |
| Third: AMAP-2 plus assessment | 0.5094 | 0.4075-0.6113 | Triangular (0.4075, 0.5093, 0.6113) |
| Identified as high-risk | 0.2201 | 0.1761-0.2641 | Triangular (0.1761, 0.2201, 0.2641) |
| Remainder as low-risk | 0.7799 | 0.7359-0.8239 | Triangular (0.7359, 0.7799, 0.8239) |
| Quarterly transition probability from cirrhosis to HCC | |||
| Low-risk | 0.0020 | 0.0020-0.0024 | Triangular (0.0020, 0.0020, 0.0024) |
| High-risk | 0.0328 | 0.0263-0.0328 | Triangular (0.0263, 0.0328, 0.0328) |
- Citation: Zhang YB, Li YX, Zhang WD, Hou XB, Li R, Xia RY, Shen MW, Zou ZR, Zhuang GH. Cost-effectiveness of risk-stratified hepatocellular carcinoma screening using the age-male-albumin-bilirubin-platelets score-based stepwise enrichment approach in patients with cirrhosis. World J Gastroenterol 2026; 32(46): 121840
- URL: https://www.wjgnet.com/1007-9327/full/v32/i46/121840.htm
- DOI: https://dx.doi.org/10.3748/wjg.121840